{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-074428","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.297497+00:00","generated_at":"2026-05-21T01:48:22.571611+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CRISPR Therapeutics enters collaboration with Sirius on FXI-targeting siRNA; positive Phase 1 data","bullets":["Upfront consideration: $70M in common shares + $25M cash to Sirius for co-development of FXI-targeting siRNA SRSD107.","Potential milestones: up to $340M for opt-out and up to $87.5M for development/regulatory; royalties mid-single to low-double digit.","Phase 1: single doses well tolerated, >93% reduction in FXI levels and activity, sustained up to six months post-dosing.","Phase 2 trial initiated for prevention of venous thromboembolism in patients undergoing total knee arthroplasty.","Company has options to exclusively license Sirius siRNA technology for up to two additional targets; $10M option fee per target."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-074428","json":"https://secwatch.observer/filing/0000950170-25-074428.json","markdown":"https://secwatch.observer/filing/0000950170-25-074428.md","text":"https://secwatch.observer/filing/0000950170-25-074428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025074428/0000950170-25-074428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025074428/crsp-20250519.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T01:48:22.571611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}